With 1.28 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.9 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $13.67 whereas the lowest price it dropped to was $13.18. The 52-week range on MYGN shows that it touched its highest point at $29.30 and its lowest point at $12.87 during that stretch. It currently has a 1-year price target of $21.62. Beta for the stock currently stands at 1.90.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MYGN was down-trending over the past week, with a drop of -3.33%, but this was down by -9.72% over a month. Three-month performance dropped to -48.59% while six-month performance fell -44.65%. The stock lost -33.25% in the past year, while it has lost -28.68% so far this year. A look at the trailing 12-month EPS for MYGN yields -1.30 with Next year EPS estimates of 0.15. For the next quarter, that number is 0.03. This implies an EPS growth rate of 147.30% for this year and 16.39% for next year.
Float and Shares Shorts:
At present, 91.00 million MYGN shares are outstanding with a float of 87.62 million shares on hand for trading. On 2024-11-29, short shares totaled 3.39 million, which was 372.0 higher than short shares on 1730332800. In addition to Mr. Paul J. Diaz J.D. as the firm’s CEO, President & Director, Mr. Samraat S. Raha serves as its Chief Operating Officer.
Institutional Ownership:
Through their ownership of 1.02297 of MYGN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, MYGN reported revenue of $213300000.0 and operating income of -$17800000.0. The EBITDA in the recently reported quarter was -$2600000.0 and diluted EPS was -$0.24.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MYGN since 7 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 5 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MYGN analysts setting a high price target of 35.0 and a low target of 13.0, the average target price over the next 12 months is 22.53333. Based on these targets, MYGN could surge 156.41% to reach the target high and fall by -4.76% to reach the target low. Reaching the average price target will result in a growth of 65.08% from current levels.
Analysts have provided yearly estimates in a range of $0.13834 being high and $0.095775 being low. For MYGN, this leads to a yearly average estimate of $0.1277. Based on analyst estimates, the high estimate for the next quarter is $0.05 and the low estimate is -$0.04. The average estimate for the next quarter is thus $0.0.
